Protein profiles (proteomics) discriminating between effect/no effect of weekly paclitaxel: A phase II study in metastatic breast cancer (BC)

B. K. Linderholm; J. Lehtio; E. Lidbrink; E. Ekman; P. Karlsson; A. von Wachenfeldt; B. Norberg; L. Carlsson; T. Hatschek; R. Lewensohn

doi:10.1200/jco.2005.23.16_suppl.699

Protein profiles (proteomics) discriminating between effect/no effect of weekly paclitaxel: A phase II study in metastatic breast cancer (BC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.699 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 699-699

Author(s):

B. K. Linderholm ◽

J. Lehtio ◽

E. Lidbrink ◽

E. Ekman ◽

P. Karlsson ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Protein Profiles

Download Full-text

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

British Journal of Cancer ◽

10.1038/sj.bjc.6601485 ◽

2004 ◽

Vol 90 (1) ◽

pp. 36-40 ◽

Cited By ~ 47

Author(s):

S Gori ◽

M Colozza ◽

A M Mosconi ◽

E Franceschi ◽

C Basurto ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Pretreated Patients

Download Full-text

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

Breast Cancer Research and Treatment ◽

10.1007/s10549-016-3851-7 ◽

2016 ◽

Vol 158 (1) ◽

pp. 91-97 ◽

Cited By ~ 21

Author(s):

L. M. Smyth ◽

N. M. Iyengar ◽

M. F. Chen ◽

S. M. Popper ◽

S. Patil ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Progression Free Survival ◽

Weekly Paclitaxel ◽

Free Survival

Download Full-text

Weekly paclitaxel (P) combined with biweekly vinorelbine (V) in metastatic breast cancer (MBC): Final results of a clinical phase II study

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.783 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 783-783

Author(s):

T. Bouillet ◽

P. Saintigny ◽

E. Levy ◽

J.-P. Spano ◽

F. Morin ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Clinical Phase

Download Full-text

Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.607 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 607-607

Author(s):

Lillian Mary Smyth ◽

Neil M. Iyengar ◽

Sarat Chandarlapaty ◽

Steven Sugarman ◽

Elizabeth Anne Comen ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Progression Free Survival ◽

Weekly Paclitaxel ◽

Free Survival ◽

Survival Result

Download Full-text

Phase II study of weekly paclitaxel for docetaxel-resistant or -inapplicable metastatic breast cancer: Preliminary results

European Journal of Cancer ◽

10.1016/s0959-8049(02)80221-0 ◽

2002 ◽

Vol 38 (11) ◽

pp. S73

Author(s):

T Ajhara

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Preliminary Results

Download Full-text

Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.1119 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 1119-1119 ◽

Cited By ~ 2

Author(s):

Y. Ito ◽

K. Aogi ◽

N. Masuda ◽

S. Ohno ◽

T. Oda ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

First Line

Download Full-text

Abstract P5-18-20: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer.

10.1158/0008-5472.sabcs12-p5-18-20 ◽

2012 ◽

Cited By ~ 4

Author(s):

F Datko ◽

G D'Andrea ◽

M Dickler ◽

M Theodoulou ◽

S Goldfarb ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel

Download Full-text

Abstract CT131: A randomized (RCT) phase II study of oncolytic reovirus (pelareorep ) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC)

10.1158/1538-7445.am2017-ct131 ◽

2017 ◽

Cited By ~ 1

Author(s):

Vanessa Bernstein ◽

Susan Ellard ◽

Susan F. Dent ◽

Karen A. Gelmon ◽

Sukhbinder K. Dhesy-Thind ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel

Download Full-text

Phase II Study of Weekly Paclitaxel for Docetaxel-Resistant Metastatic Breast Cancer in Japan

The Breast Journal ◽

10.1111/j.1075-122x.2004.21555.x ◽

2004 ◽

Vol 10 (6) ◽

pp. 509-513 ◽

Cited By ~ 17

Author(s):

Tetsuya Taguchi ◽

Tomohiko Aihara ◽

Yuichi Takatsuka ◽

Eisei Shin ◽

Kazuyoshi Motomura ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel

Download Full-text

Abstract P2-16-07: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data

10.1158/0008-5472.sabcs13-p2-16-07 ◽

2013 ◽

Cited By ~ 1

Author(s):

NM Iyengar ◽

FM Datko ◽

G D'Andrea ◽

MN Dickler ◽

S Goldfarb ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Paclitaxel ◽

Cardiac Biomarker ◽

Biomarker Data

Download Full-text